What is Anti-E (Anti-E antibody) in an autoantibody test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Anti-E is an antibody that targets the E antigen found on red blood cells as part of the Rh blood group system, and its presence can lead to hemolytic transfusion reactions or hemolytic disease of the fetus and newborn if not properly managed. This antibody can develop when a person lacking the E antigen is exposed to E-positive red blood cells, typically through blood transfusion or during pregnancy 1. Anti-E antibodies are detected through antibody screening tests, which are routinely performed before blood transfusions or during pregnancy to identify potential incompatibilities.

Key Points to Consider

  • These antibodies can cause hemolytic transfusion reactions if E-positive blood is given to someone with anti-E antibodies, or hemolytic disease of the fetus and newborn if a pregnant woman with anti-E antibodies carries an E-positive fetus.
  • While anti-E is generally considered a clinically significant antibody, it often causes milder reactions compared to other Rh antibodies like anti-D.
  • Management typically involves providing E-antigen negative blood for transfusions in affected individuals and monitoring pregnancies where the mother has anti-E antibodies to assess the risk to the fetus.
  • In some cases, warm autoimmune hemolytic anemia with mimicking anti-e specificity can cause intravascular hemolysis, and treatment with steroid and rituximab therapy may be necessary 1.

Treatment Approach

  • The treatment approach for autoimmune hemolytic anemia, including cases involving anti-E antibodies, may involve corticosteroids as first-line therapy, with the addition of rituximab considered in severe cases or if no prompt response to steroids is achieved 2.
  • Rituximab with or without bendamustine may be used in the first line for patients with cold agglutinin disease requiring therapy 2.
  • Providing E-antigen negative blood for transfusions in affected individuals and monitoring pregnancies where the mother has anti-E antibodies to assess the risk to the fetus is crucial for preventing complications associated with anti-E antibodies 1.

References

Research

Warm autoimmune hemolytic anemia with mimicking anti-e specificity causing intravascular hemolysis in a chronic ITP patient.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.